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In the past 25 years the treatment of shock in myocardial
infarction has evolved into a physiologicapproach based
on on-line measurements of hemodynamic variables. This
has aided in the development of new pressor agents so
that a family of pharmacologic agents is now available.
Appropriate use of vasodilators and recognition and
treatment of intravascular volume depletion have in-
During the past 25 years there have been major advances
in our understanding of the pathophysiolo gy of shock as-
sociated with acute myocardial infarction . Some would sug-
gest that these advances have not affected outcome. but this
is not true. By substituting pump failure for shock to define
the syndrome, the patient population has been broadened to
include those with normotensive shock and heart failure .
Therefore , although there is some artificiality in data show-
ing improved survival. there is also ev idence of earlier and
more appropriate intervention . It is probable that if most
patients included in the broader definit ion had been treated
before hemodynamic assessment was routine and before the
current spectrum of vasodilators and pressor agents was
avail able, their condition would have progressed to hypo-
tensive shock and then to expected death. Thus, early hemo-
dyn amic assessment and appropriate early therapy have in-
creased survival (I). There is no doubt that recognition of
volume depl etion in this syndrome has improved surv ival.
More recentl y, mechanical support and surgical interven-
tion , when appl ied appropriately, have been shown to im-
prove survival (2) .
Hemodynamics
In understanding the pathophysiology of shock in myo-
cardial infarction , we must credit investigation s in animals
and human beings that demonstrated the interaction of myo-
cardial chemoreceptors and baroreceptors with the well known
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creased survival. Recognition and appropriate treatment
of the preshock state have decreased the incidence of
shock. The criteria for use of mechanical support and
surgical intervention are soundly established; the use of
thrombolytic therapy and balloon angioplasty for this
syndrome is ready to be evaluated.
carotid sinus and aortic baroreceptors (3-5). Demonstra-
tions which showed that integration of these receptor im-
pulses by the central nervous system causes uneven re-
sponses in various vascular beds help explain the dichot omy
of marked vasoconstriction by clinical appearance while
hemodynamic data have indicated an inappropriate lack of
increase in vascular resistance .
Althou gh there were a few early studies of hemod y-
namics in patients with shock in myocardial infarction (6) ,
it was not until the mid I960s that large numbers of patient s
were studied. Our group at Cook County Hospital (7) . and
that of Cohn et al. (8) in Washington, studied such patients
using direct measurement of left ventricular pressures. Fal-
icov and Resnekov (9) proposed the use of pulmonary artery
pressure for such monitoring. However, it was the catheter
developed by Swan and Ganz et aJ. (10) that facilitated
frequent bedside measurements of left ventricular filling
pressure.
Most house officers today can make repeated measure-
ments of cardiac output , pulmonary artery pressures and left
ventricular filling pressures using a small transducer with a
disposable packaged manifold and a small easily balanced
bedside monitor. It is surely impo ssible for them to appre-
ciate the cumbersome mass of equipment required to derive
the same information only 20 years ago in specialized re-
search units. This is perhaps one of the best examples of
the direct translation of research into standard accepted med-
ical practice .
Initial Therapy
In this report, we attempt to state where we stand now in
the therapy of the shock syndrome in patients with acute
myocardial infarction. We hypothetically assume that the
diagnosis is established and the patient has been given small
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amounts of morphine intravenou sly to relie ve pain , that
oxygen is being administered by cannula or mask and that
any arrhythmias that may be the prim ary cause of hemo-
dynamic deterioration have been treated. If the patient is
expending a great deal of work in breathing, an adequ ate
airway and mechanical respiratory assistance must be pro-
vided. A patient who is profoundl y hypotensive should re-
ceive norepinephrine bitartrate as initial therapy to maintain
arterial pres sure and left ventricular filling pressure . By
out evalu ation.
Hemodynamic information essential to therapy includes
the data obtained from the direct measurement of intra-
arterial pressure and left ventricular filling pressure . By
using a thermodilution Swan-Ganz cath eter, one can also
measure right atrial and pulmonary artery pressures and
cardiac output. Heart rate and rhythm are measured by a
constant electrocardiographic monitor. Urin ary flow is mea-
sured by collection from an indwelling catheter.
Recognition and therapy of volume depletion. From
the hem odynamic data available, one should determine al-
most immediately whether the patient is volume-depleted
becau se this condition should be corrected early. There are
several cardiovascular and iatrogenic causes of volume de-
pletion in patients with myocardial infarct ion, and recog-
nition of a cause may be very helpful in diagnosis (I). When
it is obvious that the patient is volume-depleted , one should
also con side r unrelated causes of sudden volume deplet ion
such as gas trointestinal bleeding and sepsis . Occasionally a
patient with a recent myocard ial infarction develop s shock
syndrome from urinary tract infection , but because of the
obvious acute myocardial infarction, the shock syndrome is
attributed to myocardial damage . The sepsis is not recog-
nized until hemodynamic data reveal hypovolemia and good
left ventricular function.
If the patient is in a low output state and the fillin g
pressure of the left ventricle is less than 15 mm Hg , prompt
volume expansio n should be initiated to challenge the in-
trava scular volume and raise left ventricular filling pressure
to 18 to 20 mm Hg. Slow volume infusio ns that do not
abruptly expa nd intravascular volume can lead to pulm onary
edema without significantly altering left ventricular filling
pressure. We prefer 5% albumin solution or dextran to saline
solution; the latter is frequently used , but can leak qu ickly
from the intravascular compartment and result in increases
in edema when the patient is not volume-depleted. If the
clinical condition has not improved and the low output state
persists after the left ventricular pressure has increased to
18 to 20 mm Hg, one must assume that the patient has
cardiogenic shoc k.
Pressor and Inotropic Therapy
Controversy over the use of inotropic or pressor agents in
the shock syndrome has led to more confu sion than under-
standing. At first, we were told to use pure pressor agent s
such as methoxamine because use of an inotropic agent was
like " beating a tired horse ." Later , we were convinced that
pure inotropic agents were best because pressure work is
more cos tly to the heart than volume work (II). It appears
that we have now come to the age of reason, and use pressor
and inotropic agents on the basis of a patient's physiologic
need s.
Vasopressor therapy. Ifthe patient with an acute myo-
cardial infarction, hypoten sion and shock has an elevated
left ventricular filling pressure , the first order of therapy
must be to establish a reasonable arterial pressure . If the
arter ial pressure initia lly has been low, we would begin with
an infusion of norep ineph rine to increase the systolic pres-
sure to 100 to 110 mm Hg . Under these circum stances,
norepinephrine has been shown (12) to increase cardiac
output and arterial pres sure. Only when the arterial pre ssure
is incre ased well above these levels does cardiac output
begin to decline . However , prolonged infusion or increasing
dosage of norep inephrine cannot be ju stified. One must be
able either to subs titute less potent agents qu ite promptl y
after hem odynamic status has been stabilized, or to add
mechan ical support .
If the arterial systolic pressure is between 70 and 90 mm
Hg, then dopamine hydrochloride can be illfused at a rate
ranging between 0.2 and 1.0 mg/min (13). Dopamine is a
potent sympathomimetic amine that acts through the alpha-
and beta-receptors and receptors peculiar to dopamine, caus-
ing vasodi lation of the mesenteric and renal arterioles (14).
The se vasodilator receptors are overwhelmed with larger
doses of dopamine because alpha-receptor activity causes
vasoconstric tion of these vessels . At small doses the pre-
dominant effect of dopamine is throu gh stimulation of the
beta- and dopaminergic receptors. Dopamine has significant
chronotropic effect, causing tachycardia and occasionaIly
ventricular arrhythmias including ventricular tachycardia. It
increa ses cardiac output and will accomplish this increase
more effective ly than will norep inephrine in patients with
mild hypotension (\ 5). Dopamine is less effective than
isoproterenol in increasing cardiac output, but it does not
cause the marked vasodilation of the skeletal muscle vas-
culature seen with isoproterenol ( 16) . Thu s, the increased
cardiac output during dopamine infusion is directed more
appropriatel y to the vital organs; it is aided somewhat by
mild alpha-adrenergic vasoconstriction. As the rate of in-
fusion is increased beyond 1.0 mg/min, the alpha-adrenergic
vasoconstrictor effect becomes increa singly dominant until ,
finally , the agent acts much like norepinephrine . If the effect
of norep inephrine is desired , then switching to norep ineph -
rine would be more appropriate unless the chronotropic ef-
fect of dopamine is also desired. Conversely , vasodilators
such as phentolamine or nitroprusside can be added to negate
the alpha-adrenergic vasoconstriction and, thus, acce ntuate
cardi ac output (17). Th is use of vasodi lators involves first
stabilizing arterial pressure between 100 and 110 mm Hg
systolic and then adding the vasodilator. watching carefully
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to see that the arterial pressure does not decrease. If the
mean or diastolic pressure decreases too much with the use
of vasodilators during infusion of dopamine or norepineph-
rine, the work of the heart will increase while the trans-
myocardial pressure gradient. on which coronary blood fl ow
depends. is reduced.
Dobutamine. In patients with the shock syndrome who
are not seriously hypotensive but who have a low output
state or severe pump failure and do not meet all the clinical
criteria of shock, either vasodilators or dobutamine hy-
drochloride. or a combination of these agents can be infused.
Vaosdilator therapy is particularly effective in patients with
pulmonary edema whose arterial pressures are well within
the normal range or only slightly elevated. Vasodilators
should be the initial treatment in these circumstances. How-
ever, if the low output state predominates and pulmonary
congestion is not a major clinical problem, then dobutamine
may be the preferred agent for initiating therapy. Dobuta-
mine is a synthetic sympathomimetic amine that was produced
by Tuttle and Mills (18) by modifying the dopamine struc-
ture. It acts directly on the adrenergic receptors, and does
not depend on release of norepinephrine for its activity.
Dobutamine has been shown to have a major inotropic effect
with what appears to be an attenuated chronotropic effect.
The peripheral vascular effects are minimal in the experi-
mental animal (19), and the vasodilation seen during in-
fusion of dobutamine in the patient with heart failure is due
to the withdrawal of sympathetic tone as cardiac output is
increased (20). By selective receptor blockade. dobutamine
can be shown to have very minimal alpha- and beta-adre-
nergic effects on the peripheral vasculature (19). In patients
with congestive heart failure dobutamine reduces left ven-
tricular filling pressure as it increases cardiac output, unlike
dopamine. which in similar patients frequently increases left
ventricular filling pressure (21).
Gillespie et al. (22) used dobutamine in a group of pa-
tients with acute myocardial infarction and found no evi-
dence of an increase in myocardial damage or oxygen re-
quirements despite increasing cardiac work. It may be that.
with dobutamine, the decrease in ventricular volume re-
flected in the decreased filling pressure more than compen-
sates for the increased cardiac work by decreasing wall
tension and, thus, myocardial oxygen requirements are little
changed. Dobutamine does not have a direct vasodilator
effect on the renal vasculature or mesenteric vessels. but
does increase urinary flow by its effect on cardiac output
and subsequent proportional increase in renal blood flow
(23). Administration of dobutamine should not be continued
in the patient who becomes hypotensive. because dobuta-
mine will not support the arterial pressure except by its effect
on cardiac output. In general. the systolic pressure increases
slightly and diastolic pressure decreases as a manifestation
of the increased stroke volume. In many patients with heart
failure, dobutamine increases cardiac output to a greater
extent than does nitroprusside (24). However, in patients
with high vascular resistance it can be used quite effectively
in combination with nitroprusside. thus providing a greater
increase in cardiac output at a reasonable dosage of
dobutamine.
Vasodilator Therapy
Although Burch (25) proposed vasodilators for the treatment
of heart failure in 1956. this therapy did not become popular
until the I970s (26). Even then. most clinicians were fearful
that using vasodilators in patients with acute myocardial
infarction might precipitously reduce arterial pressure and
thereby diminish coronary artery perfusion pressure. As stu-
dents, most of us were warned against using nitroglycerin
in patients with acute myocardial infarction. The availability
of constant hemodynamic monitoring. a variety of pressor
agents and mechanical circulatory assistance made such a
decrease in pressure less onerous. With the realization that
many patients with acute myocardial infarction and clinical
shock had adequate central aortic pressure, investigators
began treating this syndrome with vasodilators. By consid-
ering the broad spectrum of pump failure and the need to
decrease the work of the heart early in the course of this
syndrome, it became obvious that vasodilators are excellent
therapeutic agents for such patients.
Nitroprusside. Because of its ease of administration,
nitroprusside has been proposed for treatment of patients
with acute myocardial infarction and pump failure (27).
However. there are two areas of controversy concerning its
use in this syndrome. The fi rst concerns the pressure level
at which nitroprusside can be given safely; the second is
the possibility that nitroprusside will cause additional myo-
cardial damage. Most investigators agree that vasodilators
are not safe agents if systolic pressure is less than 90 mm
Hg. but that they can be very effective if left ventricular
filling pressure is high and the systolic arterial pressure is
greater than 110mm Hg. In patients whose systolic pressure
is between 90 and 110 mm Hg, clinical judgment must
determine if vasodilators can be used. Moment to moment
hemodynamic monitoring is necessary during vasodilator
therapy in these hemodynamically fragile patients and a
vasopressoragent may have to be added or substituted quickly
if there is a signifi cant reduction in arterial pressure. Oc-
casionally, volume will have to be added if filling pressures
decrease too abruptly. Most patients will have some reduc-
tion in arterial pressure when given nitroprusside. Arterial
pressure will increase in some patients as nitroprusside is
infused, but these instances are unusual. It is apparent that
if both ventricular volume and the vascular resistanceagainst
which the left ventricle is operating are reduced. systolic
wall tension is lowered and myocardial oxygen requirements
are decreased. However, a consequent decrease in arterial
pressure could lead to a decrease in myocardial perfusion.
particularly to areas distal to partially obstructed coronary
arteries.
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Phentolamine, nitroprusside and nitroglycerin.
These vasodilators, although grouped together and all rec-
ommended for treatment of pump failure, should not be
considered interchangeable (28). Phentolamine is a dilator
of arteriolar resistance vessels, and its effect on the periph-
eral vessels may be more profound than its effect on the
coronary vessels (29). Nitroglycerin, in contrast, has its
major vasodilating effect on the venous capacitance system,
and reduces ventricular work and volume by pooling blood
in the venous system. Nitroglycerin does affect the coronary
artery conductance vessels, but has very little effect on the
arteriolar resistance vessels (30). The decrease in arterial
pressure from nitroglycerin is mainly due to a reduction in
cardiac output as cardiac inflow is reduced. Nitroprusside
has a very potent effect on the resistance vessels of the
myocardium as well as on the peripheral vessels, and also
is active in causing dilation of the venous capacitance ves-
sels. All three agents may induce an increase in sympathetic
tone by decreasing arterial pressure, thus producing a reflex
response through baroreceptor activation. In addition, there
is evidence that phentolamine has a direct chronotropic ef-
fect that may be due to blockade of alpha--receptors (31).
In patients with heart failure, the reflex increase in sym-
pathetic tone is attenuated during infusion of these agents
because the sympathetic system is already activated by heart
failure. There have been reports that the tachycardia with
nitroprusside infusion is much less pronounced in patients
being treated for heart failure (32).
The differences between the effect of nitroglycerin and
nitroprusside for treatment of acute myocardial infarction
hinge on the action of these drugs on the various vascular
beds. Some investigators (33) have shown that myocardial
damage is increased in experimental animals, and perhaps
in human beings, when nitroprusside is given during the
early phase of acute myocardial infarction (34). It is thought
that the reduction in arterial pressure that occurs after ni-
troprusside infusion decreases coronary flow and, although
the work of the heart is decreased, the direct effect of ni-
troprusside on the arteriolar resistance vessels in nonisch-
emic areas is to dilate these vessels and allow preferential
flow to normal myocardium. The ischemic myocardium is
distal to partially obstructed vessels, and in those areas the
decrease in systemic pressure, combined with the decrease
in pressure across the obstruction, will result in distal cor-
onary artery pressures that are insufficient for myocardial
perfusion. However, with nitroglycerin, the increased sym-
pathetic stimulation that derives reflexly from the decrease
in arterial pressure causes vasoconstriction of the arteriolar
resistance vessels in the myocardium, which is not overcome
by any direct action of nitroglycerin on these vessels (33).
Thus, the resistance vessels in the normal myocardium tend
not to dilate, while those in the ischemic myocardium remain
dilated due to the ischemia. When nitroglycerin is used,
blood is preferentially diverted to rather than away from the
ischemic area, assuming that central aortic pressure remains
adequate.
Beneficial versus detrimental effects. Part of the rea-
son for the controversy regarding use and abuse of nitro-
prusside is that various groups of patients are being de-
scribed, and this fact is not always emphasized in the
therapeutic recommendation. If the patient is very hyper-
tensive with severe left ventricular failure, severe mitral or
aortic insufficiency or ventricular septal rupture, the bene-
ficial effects of nitroprusside are much greater than any
detrimental effects that would appear from the described
diversion of blood flow from the ischemic area. In patients
with severe mitral insufficiency, the regurgitant fraction is
reduced and arterial pressure is improved with the use of
nitroprusside as ventricular volume decreases and the mitral
valve becomes competent (35). In patients with an acute
ventricular septal defect, a similar relation would pertain;
and preferential shunt flow would shift toward aortic flow
as the arterial peripheral vascular resistance is decreased.
Thus, the use of nitroprusside in patients with acute myo-
cardial infarction and heart failure can be quite successful.
If arterial pressure begins to decrease or cardiac output is
not increased sufficiently, then either dopamine in the for-
mer situation or dobutamine in the latter situation could be
added to stabilize arterial pressure or further increase cardiac
output, or both. Ifthe problem is persistent pain rather than
pump failure, intravenous nitroglycerin or a calcium channel
blocking agent would be the vasodilator of choice.
Results of Pharmacologic Therapy
Early experience. Our first reported experience in 1966
(12) of treating patients with acute myocardial infarction
with shock and severe hypotension revealed that vasopressor
agents, norepinephrine in particular, could increase the
cardiac output and arterial pressures of patients with this
syndrome. Of the 11 patients treated with norepinephrine
in this series, 3 survived the shock episode, but only I
recovered sufficiently to leave the hospital. In the early
reports of treatment of shock, most investigators defined
recovery as recovery from shock with survival for more than
24 hours after discontinuation of all vasopressor support.
The more logical and current definition of recovery is sur-
vival and discharge from the hospital, and this is usually
accompanied by some evaluation of the functional status of
the patient. In our series, the only patient who recovered
and was a long-term survivor had responded to volume
expansion in addition to vasopressor agents. At the time, it
was proposed that volume depletion might have been a
significant factor in the development of the shock syndrome.
It was later suggested (11) that isoproterenol might be a
better agent than norepinephrine for treating patients with
shock due to myocardial infarction. However, a comparative
trial of these two agents revealed that most patients with
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acute myocardial infarction , shock and hypotension did very
poorl y with isoproterenol (16) . The only exceptions were
patients who had marked bradycardia or severe valvular
insufficiency . Today, because of frequent use of temporary
pacemakers and vasodilator agents, these latter conditions
are no longer considered an indication for isoproterenol
therapy .
Later experience. In 1977, we (36) reviewed our ex-
perience in treating patients with shock associated with acute
myocardial infarction . We found that with pharmacologic
agents alone only 3 of 39 patients with true hypotensive
cardiogenic shock survived to leave the hospital, and all of
these patients were in functional clas s III or IV at the 6
month follow-up study. After vasodilator agents were sug-
gested as an alternative to pressor therapy , prognosis ap-
peared to improve. Although use of these agents was a
significant step forward in the therapy of shock, one must
be careful to define accurately the patient group being treated
(37). Our study, and most studies of that era . included an
intraarterial systolic pressure of less than 90 mm Hg as one
definition of the shock syndrome . It was recognized that the
clinical syndrome , and even low cuff pressure , could be
present in patients with adequate systolic or mean intraar-
terial pressures, but such patients had not been included in
the early series cited.
In 1972, Franciosa et al. (27) reported improved ven-
tricular function with nitroprusside infusion in patients with
myocardial infarction and demonstrated that the work for-
mula could be shifted to increased flow by decreasing sys-
tolic pressure, thereby effecting a decrease in filling pres-
sure. Thus , an increase in cardiac output could be achieved
at lower myocardial oxygen cost. Chatterjee et al. (38) re-
ported on 38 patients with severe pump failure and acute
myocardial infarction and demonstrated a decrease in left
ventricular filling pressure, an increase in cardiac index and
a decrease in systemic vascular resistance . Vasodilator ther-
apy included nitroprusside or phentolamine in sufficient dos-
age to produce "significant beneficial hemodynamic effects
with less than 20 mm Hg drop in mean arterial pressure."
In their series , 17 patients were considered to have shock
by a definition that included a cuff pressure of less than 90
mm Hg and the usual clini cal indexes of shock. Of the 17
patients pre senting with shock, 8 survived the hospitaliza-
tion, but only 2 were long-term survivors. These patients
had a mean (± standard error of the mean) arterial pressure
of 83 ± 1.5 mm Hg on intraarterial measurements, and it
is impossible from the data presented to compare these pa-
tients with the patients with hypotensive shock reported on
previously. The patients who survived probably did not have
intraarterial hypotension, because the benefits of therapy
were associated with a significant reduction of arterial pres-
sure. However, this work did advance the therapy of patients
with severe pump failure, pulmonary congestion and clinical
shocklike states . It is probable that the mortality rate would
have been higher if these patients classified as having shock
had been treated with pressor agents as they would have
been during the era preceding that which practiced careful
intravascular hemodynamic evaluation of the severely ill
patient.
Awan et al. (39) describ ed the use of nitroprusside in 12
patients with acute myocardial infarction . They excluded
patients with a systolic arterial pressure of less than 100
mm Hg . Only four of the patients had a wedge pressure of
less than 15 mm Hg, and the mean wedge pressure for the
group was 18.5 mm Hg . These inve stigators demonstrated
a decrease in ST segment elevation with the infusion of
nitroprusside unlike Chiariello et al. (33 ). who demonstrated
an increase in ST segment elevation after nitroprusside .
There was no significant difference in the control arterial
pressures of the two groups , but the increase in heart rate
appeared to be greater in the patients treated by Chiariello
and co-workers. Group differences in ventricular volumes
or in time from onset of infarction may have caused the
different outcome in the two groups. The se finding s em-
phasize the need for careful classification of patients before
conclusion s regarding efficacy of therapy are reached .
Thu s. the addition of vasodilators to the therapy of pa-
tients with acute myocardial infarction and the shock syn-
drome or pump failure has been a great contribution. How-
ever, these patients must be differentiated from those with
hypotensive cardiogenic shock, almost all of whom die when
treated without mechanical or surgical intervention .
Current Therapeutic Recommendations
Because hemodynamic monitoring is now standard in ther-
apy of the shock state , it is possible to classify patients into
hemodynamic subsets and initiate and adjust therapy in a
logical manner. Subset I includes patients with a left ven-
tricular filling pressure greater than 18 mm Hg and an arterial
systolic pressure of 110 mm Hg or more: these patients
should be treated first with vasodilators. Subset 2 includes
patients who also have a left ventricular filling pressure
greater than 18 mm Hg but an arterial systolic pressure of
90 mm Hg; the condition of these patients should be sta-
bilized first with vasopressors. The patients in subset 2 have
a poor prognosis because they have the most severe left
ventricular dysfunction and salvage almost always requires
early initiation of mechanical support . In patients with a
high left ventricular filling pressure but an arterial systolic
pressure between 90 and 110 mm Hg. clinical judgment is
required to determine whether to initiate therapy with pres-
sors or vasodilators. With constant hemodynamic monit or-
ing , it is possible to change to or add the other agent after
observing the patient ' s initial respon se . Subset 3 include s
patients with a left ventri cular filling pressure of less than
15 mm Hg; these patients should be treated first with an
intravascular volume challenge. Subset 4 includes patients
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with the shock syndrome and a high right ventricular filling
pressure in whom right ventricular infarction and pulmonary
embolism should be considered. In these instances it may
be necessary to add volume to the regimen chosen. The
exact dosages of agents for treatment of these subsets re-
cently were outlined in detail in the Proceedings of the
Bethesda Conference on Emergency Cardiac Care (40).
Intraaortic Balloon Counterpulsation
Hemodynamic effects. Patients with acute myocardial
infarction who have cardiogenic shock or persistent left
ventricular failure despite vasodilator therapy frequently re-
spond best to the use of mechanical support with the in-
traaortic balloon pump. This has the advantage over phar-
macologic agents in I) decreasing left ventricular filling
pressure and, therefore, left ventricular diastolic volume; 2)
decreasing ventricular systolic pressure; and 3) simulta-
neously increasing the aortic pressure during early and mid-
diastole, which is the period of greatest coronary blood flow.
Because diastolic pressure is reduced in the left ventricle
and increased in the aorta, the transmyocardial pressure
gradient is increased, and this should be particularly effec-
tive in promoting flow to regions supplied by partially ob-
structed or collateral vessels where flow is highly dependent
on proximal perfusion pressure. The reductions in left ven-
tricular volume and systolic pressure both act to decrease
wall tension and, hence, myocardial oxygen requirements.
Thus, the effects of counterpulsation are increased blood
flow to the body, increased aortic peak pressure, decreased
myocardial oxygen requirements and increased myocardial
blood flow.
Indications. In a patient with myocardial infarction and
shock or failure in whom the process of infarction is still
ongoing, it is logical that early counterpulsation would pre-
serve at least some of the marginal myocardium, and thus
improve the long-term prognosis of these patients. It is our
policy to mobilize the pump team at the time of the patient's
admission to the hospital so that within a short period the
patient can be evaluated and, if he or she truly has cardio-
genic shock due to acute myocardial infarction and not
volume depletion, the balloon pump can be inserted. This
practice also applies to patients with persistent left ventric-
ular failure, although the urgency of inserting the balloon
is not as great in these patients and pharmacologic man-
agement, including vasodilators, can be tried for a longer
period of time before balloon counterpulsation is instituted.
However, counterpulsation should not be delayed if the
patient has persistent pain or does not begin to show im-
provement with the initial pharmacologic therapy.
Associated procedures. After intraaortic balloon coun-
terpulsation has been established, pressor agents should be
withdrawn as quickly as feasible. Patients who need potent
vasopressor therapy in addition to balloon counterpulsation
have a very poor prognosis, and unless some surgical in-
tervention is feasible, they will not be candidates for wean-
ing from the pump. Nevertheless, some patients with in-
ferior infarction who have cardiogenic shock respond quite
promptly to intraaortic balloon counterpulsation (36). Some
of these patients have had long-term benefits with good
functional recovery after use of intraaortic balloon coun-
terpulsation alone, but in most instances, a patient will need
coronary angiography and left ventriculography after sta-
bilization with the intraaortic balloon.
Results of lntraaortic Balloon Counterpulsation
Early experiences. In 1968, Kantrowitz et al. (41) de-
scribed their experience with intraaortic balloon counter-
pulsation in a group of patients with cardiogenic shock.
Mueller et al. (42) measured myocardial oxygen consump-
tion, coronary blood flow and hemodynamics in 21 patients
with cardiogenic shock secondary to acute myocardial in-
farction. They were able to demonstrate that both norepi-
nephrine and intraaortic balloon counterpulsation iricreased
arterial pressure and shifted myocardial lactate production
to extraction. They found increased cardiac output only in
the patients subjected to counterpulsation, and although
myocardial oxygen consumption increased in the presence of
continued abnormally high myocardial oxygen extraction at
the time of norepinephrine infusion, during counterpulsation
myocardial oxygen consumption remained essentially un-
changed and myocardial oxygen extraction shifted toward
normal. Despite these results showing improved myocardial
metabolism, only I of the 12 patients treated with counter-
pulsation survived to leave the hospital. The first major
experience with counterpulsation for treatment of myo-
cardial infarction with shock was a cooperative study re-
ported by Scheidt et al. (43) and included 87 patients in
whom myocardial infarction, hypotension and shock were
carefully documented. Only 15 (18%) of these patients sur-
vived to leave the hospital. This rather gloomy outlook for
the use of the balloon pump must be kept in the perspective
of a very early cooperative study in which the protocol
required intraarterial systolic pressure of less than 80 rnm
Hg as well as the clinical shock syndrome. It also required
that the patients had not gained hemodynamic stability with
pressor agents before the balloon could be inserted.
Later experience. O'Rourke et al. (44) reported on 25
patients with shock and acute myocardial infarction who
were treated with counterpulsation. Three of the II patients
who were not operated on after counterpulsation survived
as did 6 of the 14 treated surgically. Of the patients treated
with counterpulsation alone only one returned to moderate
activity with mild heart failure. Of the six survivors of
treatment with counterpulsation and surgery, four had me-
chanical defects, most were active at the follow-up exam-
ination and only two had moderate disability.
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Lefemine et al. (45) reported 10 survivors among 14
patients treated with counterpulsation for cardiogenic shock.
However, they did not define the patients' hemodynamic
state in detail, and the criterion for hypotension was ap-
parently met by cuff rather than by direct measurement.
These factors, together with the lack of need to try vaso-
pressors first, may well explain the improved survival data.
These investigators also reported complications in 7 of 29
patients in their medical group, but did not identify those
patients with cardiogenic shock. All of the complications in-
volved lower limb ischemia.
Hagaemeijer et al. (46) reported on 25 patients with acute
myocardial infarction and severe pump failure. Of these 25
patients, 17 had shock. Patients over the age of 60, patients
in whom shock had begun more than 6 hours before coun-
terpulsation and patients with a new ischemic episode within
36 hours of the onset of counterpulsation were excluded
from this series. There were 8 survivors among the 17 pa-
tients with shock.
Willerson et al. (47) described 19 patients with shock
due to acute myocardial infarction who were treated with
balloon counterpulsation. Only one of these patients, a pa-
tient with acute inferior wall infarction, survived to leave
the hospital. Our own experience (36) with 18 patients with
cardiogenic shock due to acute myocardial infarction re-
vealed survival after balloon counterpulsation and without
surgery in 8 patients; 5 of these patients were in functional
class 1 or II at follow-up study. Three of these five patients
had inferior wall infarction, and one was a woman with
extensive anterior wall infarction but normal coronary ar-
teries. Therefore, it appears that intraaortic balloon coun-
terpulsation can be effective as definitive therapy for a small
group of patients with shock associated with acute myo-
cardial infarction. The evidence from Maroko et al. (48),
as well as the more recent evidence from Leinbach et al.
(49), suggests that this form of therapy preserves myocar-
dium as would be expected from its hemodynamic effects.
When a patient is in shock from acute myocardial infarction
the injury appears to progress over the first several hours,
and therefore it is reasonable to advocate intervention as
soon as possible after the patient's condition is identified.
Complications. McEnany et al. (50) reported on the
complications of balloon counterpulsation. They were un-
able to insert the balloon in only 18 of 728 patients. Vascular
complications occurred in 9.6% of the patients, and an ad-
ditional 12% had other complications such as infection,
hemorrhage or inappropriate balloon position. In patients
with shock from any cause, and particularly in those with
very low peripheral flow, ischemic complications are not
unexpected. It seems that vascular complications tend to
occur in the most severely ill patients. Advances in the
method of balloon insertion and the use of fluoroscopy dur-
ing the period of balloon insertion have kept the rate of
complications down. However, this rate is not insignificant
and must be viewed from the perspective of the desperate
nature of the patient's illness.
Surgery for Acute Myocardial Infarction
With Pump Failure
Surgically correctable lesions. Some patients with acute
myocardial infarction and shock or pump failure will be
found to have surgically correctable lesions such as severe
mitral insufficiency, ruptured ventricular septum or acute
aneurysmal infarcts that can, when repaired or resected,
leave an adequately functioning ventricle. Occasionally a
patient will have left main coronary artery stenosis or severe
proximal three vessel coronary disease with reversible global
ischemia as the major cause of pump failure. These latter
patients will respond to revascularization.
Acute revascularization. Mundth et al. (51) and Pifarre
et al. (52) demonstrated that one can accomplish acute re-
vascularization in patients with shock and myocardial in-
farction, but only during the first few hours. If such reper-
fusion cannot preserve ischemic myocardium, it is unlikely
that this early intervention can improve the shock state. In
reviewing the published data. it is not easy to determine
which patients having early revascularization actually have
cardiogenic shock due to left ventricular infarction. Shock
in some patients can be associated with acute mitral regur-
gitation or ventricular septal rupture, and these mechanical
defects can be corrected surgically.
Infarctectomy. Early performance of infarctectomy does
not often lead to survival. Early in the course, the infarcted
myocardium becomes edematous and firm with a poorly
demarcated border. Later, as the necrotic myocardium is
being removed, the infarcted area becomes more pliable and
better demarcated. It is during this latter phase that infarc-
tectomy may be beneficial. We have observed several pa-
tients develop ventricular irritability and then the shock syn-
drome at 10 to 21 days after infarction. At catheterization
these patients have had a large aneurysmal infarct, and have
greatly benefited from counterpulsation and surgery.
Clinical experience. The largest series of patients op-
erated on for shock and myocardial infarction is that reported
from Massachusetts General Hospital (53). The investiga-
tors treated 120 patients in a protocol that began with in-
traaortic balloon counterpulsation after strict criteria for the
diagnosis of cardiogenic shock had been met. General med-
ical measures were continued and, after the patient's con-
dition had been stabilized at an acceptable hemodynamic
plateau. the balloon pump was shut off and hemodynamic
measurements were repeated. If there was hemodynamic or
clinical evidence of recurrence of shock. the patient was
again given counterpulsation and then subjected to angio-
graphic study as soon as feasible. Seventeen of the 120
patients were found to be balloon-independent and were
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gradually weaned from pump support; 13 of the 17 survived
and were subjected to revascularization 4 to 6 weeks later.
Of the 103 patients found to be balloon-dependent. 26 did
not undergo angiography and subsequently died. Of the 77
remaining patients. 26 were considered inoperable after an-
giography and all died. 6 patients refused surgery and all
died. 45 were operated on and 21 survived. This would be
considered a 47% surgical survival rate in a group of patients
who would be expected to have almost no chance of sur-
vival. and a 28% survival rate for the entire group of 120
patients. This latter survival rate is certainly favorable when
compared with the 7% survival rate of patients given phar-
macologic therapy alone (36).
Our own series. although much smaller. had similar re-
sults (36). Of 19 patients treated surgically. 8 (42%) sur-
vived. The gratifying feature has been the excellent clinical
recovery of these survivors. Seven of the eight were in
functional class I and II at follow-up. compared with the
three surviving patients in our earlier series treated by phar-
macologic means alone who were all in functional class IV
at follow-up study.
Mundth (53) suggests that the patient be studied and
operated on as early as possible. Our philosophy is that
study should be performed as soon as the patient is in stable
condition. Patients with persistent ischemia. ventricular sep-
tal rupture or acute mitral insufficiency should be operated
on immediately. However, if the primary operative proce-
dure is infarctectomy, this procedure should be delayed 8
to 10 days after infarction. Unless the patient has uncon-
trollable pain. we would avoid revascularization 12 to 48
hours after myocardial infarction because there is evidence
that reperfusion injury is significant and limited to this time
interval (54).
Acute interventricular septal rupture. Interventricular
septal rupture can lead to the shock syndrome, and has a
poor prognosis if treated medically (55-57). Patients with
septal rupture respond temporarily to vasodilators and in-
traaortic balloon counterpulsation (58). but the defect is
treacherous if not corrected early after recognition. Proof
of a relatively limited shunt and hemodynamic stability can-
not be taken as reasons to delay surgery because the initial
rupture may just be a precursor of imminent severe rupture
either across the septum or into the pericardium.
We (59) recently reported our experience with 27 patients
having acute myocardial infarction and septal rupture treated
consecutively at our institution. Seven patients treated with-
out surgery died. including four who were in stable condition
and awaiting surgery at the time of death. Eleven of 20
patients survived surgery, and the patients operated on within
48 hours of septal rupture had the best prognosis.
Our own experience and several reports of successful
early surgery for ventricular septal rupture (60.61). as well
as improved techniques for repair of posterior perforations
(62), have persuaded us to revise our policy from waiting
for healing to emergency study and repair of this lesion as
soon as it is recognized.
Acute mitral insufficiency. Acute mitral insufficiency
accompanying acute myocardial infarction can be due to
papillary muscle rupture or dysfunction (63). Patients with
mitral insufficiency will respond. at least temporarily. to
vasodilators and intraaortic balloon counterpulsation. These
patients should be studied early if pulmonary congestion is
not easily controlled. If ventricular function has not been
too severely compromised. they can withstand valve re-
placement even in the first few days of acute myocardial
infarction (64).
Streptokinase and Angioplasty
The experience of the 1970s emboldened the cardiologist to
perform invasive studies earlier in the course of acute myo-
cardial infarction. In the 1980s these studies have been
supplemented with thrombolysis and balloon angioplasty.
It has been reasoned that if one could restore flow to
ischemic myocardium, then myocardial salvage should be
feasible. The logic of this approach has been applied to
acute thrombolysis and angioplasty for the treatment of shock
in acute myocardial infarction (65). Over the next few years
we will have to determine whether this degree of aggres-
siveness is appropriate and improves survival. We will also
have to give credence to those who suggest early surgical
intervention for revascularization in hyperacute myocardial
infarction (2).
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